Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

CHMP Clears GSK's Severe Asthma Drug In Europe

This article was originally published in Scrip

Executive Summary

The EMA's CHMP has issued a positive opinion recommending marketing approval for GlaxoSmithKline's mepolizumab, which is to be sold under the brand name Nucala, as an add-on treatment for severe refractory eosinophilic asthma in adult patients.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register